Galmed Pharmaceuticals (GLMD) Non-Current Assets (2013 - 2025)
Galmed Pharmaceuticals (GLMD) posted quarterly Non-Current Assets of $262000.0 for Q4 2025, up 8.26% year-over-year from $242000.0 in Q4 2024, and down 99.99% quarter-over-quarter from $1.9 billion in Q3 2025.
Galmed Pharmaceuticals (GLMD) Non-Current Assets (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Non-Current Assets history runs 13 years deep, the most recent figure standing at $262000.0 for Q4 2025.
- In Q4 2025, Non-Current Assets rose 8.26% year-over-year to $262000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 54.27% YoY), while the FY2025 annual figure was $262000.0, up 8.26% from the prior year.
- Non-Current Assets for Q4 2025 stood at $262000.0, down from $1.9 billion in the prior quarter.
- The five-year high for Non-Current Assets was $1.9 billion in Q3 2025, with the low at $242000.0 in Q4 2024.
- The 5-year median for Non-Current Assets is $1.8 million (2022), against an average of $94.6 million.
- The sharpest annual moves came in 2021 and 2025: Non-Current Assets slumped 99.9% in 2021, then soared 56867.84% in 2025.
- Galmed Pharmaceuticals' Non-Current Assets stood at $551000.0 in 2021, then surged by 233.39% to $1.8 million in 2022, then soared by 84.54% to $3.4 million in 2023, then sank by 92.86% to $242000.0 in 2024, then increased by 8.26% to $262000.0 in 2025.
- Business Quant data shows GLMD's Non-Current Assets at $262000.0 in Q4 2025, $1.9 billion in Q3 2025, and $1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 262,000.00 |
| Sep 30, 2025 | 1.86 Bn |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 2.39 Mn |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 3.27 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 3.49 Mn |
| Mar 31, 2023 | 1.96 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 391,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Mar 31, 2022 | 497,000.00 |
| Dec 31, 2021 | 551,000.00 |
| Sep 30, 2021 | 606,000.00 |
| Jun 30, 2021 | 660,000.00 |
| Mar 31, 2021 | 675,000.00 |